ACVR1 and neoplasm: Moreover, the tumor suppressive effects of BMP signaling on ACVR1 wild-type (WT) and H3.3K27M subtype DIPG are supported by clinical evidence showing that patients with high expression of CXXC5 or ACVR1 tend to have a better prognosis, while low expression of CHRDL1 is associated with improved outcomes (Sun et al. 2022).